

1 BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.
2 Patricia N. Syverson (Bar No. 203111)
Elaine A. Ryan (*Admitted Pro Hac Vice*)
3 Lindsey M. Gomez-Gray (*Admitted Pro Hac Vice*)
2325 East Camelback Road, Suite 300
4 Phoenix, Arizona 85016
Telephone: (602) 274-1100
5 Facsimile: (602) 274-1199
psyverson@bffb.com
6 Attorneys for Plaintiffs

7 (Additional Attorneys Listed on Signature Page)

8
9 **UNITED STATES DISTRICT COURT**
10 **SOUTHERN DISTRICT OF CALIFORNIA**

11 LUIS LERMA, an Individual, and NICK
12 PEARSON, an Individual, On Behalf of
Themselves and All Others Similarly
13 Situated,

Plaintiffs,

14 v.

15 SCHIFF NUTRITION
INTERNATIONAL, INC., a Delaware
16 Corporation, and SCHIFF NUTRITION
GROUP, INC., a Utah Corporation,

17 Defendants.
18

CASE NO. 3:11-CV-01056-MDD

CLASS ACTION

**PLAINTIFFS’ REPLY IN
SUPPORT OF *EX PARTE* MOTION
FOR LEAVE TO WITHDRAW
FROM SETTLEMENT**

19 **I. INTRODUCTION**

20 Nearly a year ago, the parties finalized the Settlement Agreement in this
21 matter and moved for preliminary approval of that Agreement. (*See, e.g.*, Doc. 78,
22 81.) In the interim, due to developments in other, similar cases, Plaintiffs now
23 believe that the settlement reached in this matter will draw objections that could
24 result in the settlement not being finally approved.

25 To address these concerns, on December 22, 2014, counsel for Plaintiffs and
26 Defendants filed a joint stipulation asking the Court to stay the settlement process
27 because both parties agreed “that the Seventh Circuit’s decision in *Pearson* makes
28 it appropriate for them to engage in further mediation in this case.” (Doc. 116

1 (citing *Pearson v. NBTY*, 2014 WL 6466128 (7th Cir. Nov. 19, 2014)). The Court
2 denied the requested stay and Plaintiffs’ motion to reconsider, finding that the
3 opinion in *Pearson* did not necessitate a stay of the approval process because both
4 the settlement and the law by which the fairness of the settlement would be judged
5 were different. (Docs. 116-119.) Plaintiffs and their counsel then filed the instant
6 motion requesting the Court grant them leave to withdraw from the settlement
7 because they believed “that the criticisms leveled by the Seventh Circuit towards
8 the *Pearson* settlement are likely to be raised by objectors here.” (Doc. 120 (the
9 “Motion to Withdraw”).)

10 In response, Defendants filed a 25-page Opposition to Plaintiffs’ 2-page
11 motion. (Doc. 123 (the “Opposition”).) In the Opposition, Defendants attempt to
12 distinguish this settlement and Ninth Circuit law from the *Pearson* settlement and
13 ruling. Disagreement over the impact of *Pearson*, however, is now largely beside
14 the point.

15 Of much greater concern are the likely objections to the settlement. Based
16 upon Plaintiffs’ counsel’s experience in other glucosamine related settlements,
17 objectors will rely on Ninth Circuit law recognizing the importance of obtaining
18 meaningful injunctive relief in consumer fraud class action settlements. They will
19 argue that the injunctive relief in the current settlement regarding the removal of
20 “repair/rebuild/rejuvenate cartilage/joint” representations is toothless because
21 Defendants presently use, and may continue to use, various synonyms to make the
22 same representations.

23 Indeed, Defendants’ Opposition acknowledges the possibility of objections
24 and concedes that modifications to the settlement may ultimately be “prudent to
25 address potential objectors.” (Doc. 123 at p. 11, n.8.) Such objections are not
26 hypothetical—pursuant to their request on February 20, 2015, Plaintiffs’ counsel
27 informed Defendants of one such objector, Truth In Advertising (“TINA”).
28

1 Defendants' counsel then spoke with TINA's counsel and, shortly thereafter,
2 counsel for TINA reiterated in an email that they are going to file a brief in
3 opposition to the current settlement. (Exhibit A (February 25, 2015 Email from
4 Laura Smith (TINA).) Other likely objectors include AARP (who objected to the
5 settlement in another glucosamine case, *Quinn, et al., v. Walgreen Co., et al.*, Case
6 No. 7:12-CV-8187-VB (S.D.N.Y.) ("*Perrigo*")) and Ted Frank (the objector in
7 *Pearson* who filed a declaration there stating that he also purchased Defendants'
8 Move Free product). Both TINA and AARP objected to the injunctive relief in the
9 initial *Perrigo* settlement—injunctive relief that was similar to that in the
10 settlement agreement here. The parties in *Perrigo* amended their settlement and in
11 so doing headed off the objections.

12 The fact is that the parties here share the same realistic concern regarding
13 potential meritorious objections. And it is this concern, and not the desire for a
14 bigger fee (as Defendants wrongly contend), that resulted in the Motion to
15 Withdraw. Plaintiffs believe that such objections can be mooted by modifications
16 to the settlement and that Judge Wayne Andersen, who has been involved in three
17 other glucosamine-related mediations, might be able to guide the parties to a
18 mutually agreeable resolution.

19 Yet, in their Opposition Defendants take internally inconsistent positions.
20 On the one hand, Defendants argue the current settlement is worthy of final
21 approval as it stands. On the other hand, Defendants are concerned that
22 modifications to the settlement may be needed and they do not want to issue notice
23 only to have to spend an additional \$1.5 million for a second notice. (Doc. 123 at
24 p. 11, n.8.)

25 Defendants should not be allowed to have it both ways. If Defendants
26 believe that the settlement as it now stands is sound, then the Court should order
27 them to issue notice to the class immediately, and if meritorious objections are
28

1 lodged that require a new notice, Defendants will just have to suffer the
2 consequences. If, however, and as appears to be the case, Defendants have cold
3 feet about the settlement, then they should not oppose the Motion to Withdraw or
4 attack Plaintiffs and their counsel for seeking the very thing that Defendants appear
5 to want: the opportunity to amend the settlement so that it can stand on solid
6 ground against any potential objections that might be lodged.

7 And so, rather than run the risk of proceeding with a flawed settlement that
8 will draw objections—wasting \$1.5 million of Defendants’ money and delaying
9 relief to Plaintiffs and Class members for potentially years as the settlement wends
10 its way through the appeals process—Plaintiffs request that the Court grant them
11 leave to withdraw from the settlement.

12 II. ARGUMENT

13 A. Defendants’ Opposition And Plaintiffs’ Experiences In Similar 14 Glucosamine Cases Demonstrate The Settlement Can And Should 15 Be Modified To Avoid Likely Objections.

16 Defendants’ Opposition asserts that Plaintiffs have no basis for repudiating
17 the settlement. (Doc. 123 at 12-14.) Plaintiffs’ motion does not argue that the
18 settlement agreement is not enforceable. Rather, Plaintiffs brought this motion
19 because they believe that the settlement likely will not be upheld due to objections
20 that can and should be addressed by the parties. What is more, Defendants’
21 Opposition demonstrates that, as was the case when they joined in the joint
22 stipulation, the parties agree that modifications to the settlement are needed.

23 1. Defendants’ Opposition makes it clear that Defendants 24 realize modifications to the settlement will likely be 25 required.

26 Throughout their Opposition, Defendants repeatedly make concessions
27 demonstrating that they agree that modifications to the settlement are needed.
28 (Doc. 123 at pp. 9, n.7, 11, n.8.) Defendants’ most telling concession is buried in a

1 footnote, where they discuss potential objectors. (*Id.* at p. 11, n.8.) After
2 explaining that Plaintiffs’ Counsel gave them the name and contact information of
3 one objector and requesting that Plaintiffs’ counsel be directed to provide them
4 with similar information should any other potential objectors contact them,
5 Defendants represent the following: “Schiff will then apprise the Court if after
6 communicating with those persons and entities, it would appear that some or
7 another modification to the Settlement might be prudent to address potential
8 objectors.” (Doc. 123 at p. 11, n.8 (emphasis added).)

9 This is precisely what Plaintiffs have been seeking—to stay the approval
10 process in this matter, address the potential objections that are going to be made,
11 and modify the settlement accordingly. How can Defendants insist that the current
12 agreement is sound, but not immediately cause notice to issue and, instead, conduct
13 a unilateral poll of potential objectors for some indeterminate period of time?
14 Defendants’ answer is no answer at all and that is probably why it is in a footnote
15 where Defendants claim “Schiff was in an untenable position.” (Doc. 123 at p. 9,
16 n.7.¹) The only thing that made this position untenable, though, is the thing that
17 Plaintiffs are now seeking to avoid—proceeding with a settlement that might
18 require Defendants to issue notice at a cost of approximately \$1.5 million, when
19 the possibility remains that, among other things, the settlement might ultimately
20 **have** to be modified and, as a result, notice might have to be issued again, costing
21 Defendants another \$1.5 million in expenses. *Id.*

22
23
24
25 ¹ Defendants also contend in this footnote that Plaintiffs are “implying that Schiff
26 has somehow unilaterally caused a delay in the settlement process.” (Doc. 123 at
27 p. 9, n.7.) Plaintiffs have not objected to Defendants’ failure to issue notice or seek
28 new dates to do so, as Plaintiffs have been consistently asserting that the settlement
needs to be modified.

1 Plaintiffs agree that this would be inefficient and so have been seeking to
2 avoid having notice issue until the parties determine whether modifications to the
3 settlement are needed.

4 **2. Plaintiffs' Counsel's experience in similar glucosamine**
5 **cases suggests that the settlement can and should be**
6 **modified to address anticipated objections.**

7 On February 20, 2015, pursuant to Defendants' request, Plaintiffs' counsel
8 provided Defendants' counsel with a January 21, 2015 email in which counsel for
9 TINA advised that it intended to file objections to the settlement. (*See* Exhibit B.)
10 Plaintiffs' counsel also has apprised Defendants' counsel that it is likely that the
11 AARP Foundation will file an objection consistent with the objection it filed in
12 *Perrigo*.²

13 In *Perrigo*, TINA and AARP attacked the strength of the injunctive relief,
14 similar to that here. They contended that the most important facet of small claim
15 consumer fraud settlements where the monies paid out will always pale in
16 comparison to the actual damages is whether substantial and meaningful injunctive
17 relief has been achieved by the settlement. These objections differ from those
18 raised by the objectors and accepted by the court in *Pearson*, which held that
19 injunctive relief is not a valuable benefit because it does not directly benefit the
20 class—especially where defendants are able to use synonyms to make the same
21 misrepresentations. *See Pearson*, 772 F.3d 778, 785-786.

22
23
24 ² Plaintiffs' counsel also advised Defendants' counsel that Ted Frank, the objector
25 in *Pearson*, stated in his declaration in *Pearson* that he had purchased Defendants'
26 Move Free Product. Logic dictates that since Mr. Frank is in the business of
27 objecting to settlements (he is the founder of the "Center for Class Action
28 Fairness"—an entity devoted to objecting to class action settlements, *See*
http://en.wikipedia.org/wiki/Center_for_Class_Action_Fairness) and has
succeeded in overturning a settlement similar to the one here, he is more than
likely to object to this settlement.

1 In contrast, Plaintiffs agree that injunctive relief should be meaningful and
2 that injunctive relief is an important facet of consumer fraud class action
3 settlements. So does the Ninth Circuit. *See, e.g., In re Ferrero Litig.*, 583 F.
4 App’x 665 (9th Cir. 2014) (finding that the “injunctive relief in this case is
5 meaningful and consistent with the relief requested in plaintiffs’ complaint”).³
6 Likewise, Defendants concede that injunctive relief is an important benefit that the
7 Ninth Circuit and district courts in the Ninth Circuit value. (Doc. 123 at 15-17.)
8 And, this Court has also recognized the importance of injunctive relief. (*See, e.g.,*
9 Doc. 119 at 3.)

10 Currently, the settlement provides that, for a period of 24 months,
11 Defendants shall not represent that their products “repair joints”, “repair cartilage”,
12 “rebuild joints”, “rebuild cartilage”, “rejuvenate joints” or “rejuvenate cartilage.”
13 (Doc. 107-1, Settlement Agreement IV.C. p. 13 (the “rebuild” representations).)
14 As reflected on their web site, Defendants still make these representations as well
15 as analogous representations using synonyms that their products maintain and
16 strengthen joints, that the products also protect joints and cartilage from
17 breakdown, and that they fight the breakdown of cartilage.⁴

18 At the preliminary approval hearing, this Court questioned whether allowing
19 the word “strengthens” to remain on the product labels undercut the benefit of
20 removal of the “rebuild” representations. Based on market research and the district
21 court in *Pearson* having rejected an identical objection shortly before the
22

23
24 ³ In *Ferraro*, the Ninth Circuit affirmed an attorneys’ fee award of \$985,920 due to
25 the injunctive relief that had been obtained even though there was only a \$550,000
monetary fund established. *Id.* at 668.

26 ⁴*See, e.g.,* http://www.movefree.com/about-move-free?utm_source=bing&utm_medium=cpc&utm_campaign=Brand%20-%20Move%20Free%20-%20Phrase&utm_term=what%20is%20move%20free&gclid=CPjbieCm-8MCFQVUKwodWS0A3Q&gclid=ds.
27
28

1 preliminary approval hearing,⁵ Plaintiffs’ counsel argued that even with
2 “strengthens” on the label, there was benefit to removal of the “rebuild”
3 representations. Subsequently, the Seventh Circuit held that because the injunctive
4 relief allowed the use of synonyms like “strengthens,” the injunctive relief was
5 illusory. *See Pearson*, 772 F.3d at 785.

6 Given the *Pearson* holding, counsel for the parties in *Perrigo*, who had
7 initially entered into a settlement with injunctive relief similar to that in this case
8 and similar to that struck down in *Pearson*, arrived at an amended settlement
9 agreement regarding the injunctive relief. That amended agreement now provides
10 that the settling defendant “will not make the following statements, *or statements*
11 *conveying the same message*, on the labels of any of the Covered Products as it
12 pertains to the effect of the Covered Products on cartilage, *using synonyms such as*,
13 *but not limited to: fixing, mending, reconditioning, rehabilitating, increasing,*
14 *developing, building, maintaining, strengthening, repairing, rebuilding, renewing,*
15 *regrowing, adding, regenerating or rejuvenating.”* (*Perrigo* Doc. 141, Ex. 1 at ¶ 10
16 (amended language is emphasized).)

17 This amendment eliminated all of the “language” concerns raised by the
18 Seventh Circuit in *Pearson* and effectively mooted the concerns raised by objectors
19 in that case—including TINA, which has already indicated that it intends to object
20 to the current settlement.⁶ Likewise, the Amended Settlement in *Perrigo*
21

22 ⁵ *See Pearson*, Doc. 141 (Mem. Op. at 10 dated January 3, 2014).

23 ⁶ After the amendment to the settlement in *Perrigo*, TINA posted the following
24 statement on its website: “TINA.org’s objection has had a significant impact.
25 After filing the brief, the companies and class-action attorneys revised the
26 proposed settlement agreement to forever prohibit the glucosamine marketers from
27 using any terms that convey the message that its supplements can repair, strengthen
28 or rebuild cartilage unless there is sufficient scientific evidence to substantiate the
claims and the court gives permission.” *See*
[https://www.truthinadvertising.org/wellesse-glucosamine-settlement-doesnt-cure-
ad-issues/](https://www.truthinadvertising.org/wellesse-glucosamine-settlement-doesnt-cure-ad-issues/) .

1 eliminates temporal concerns raised by the *Pearson* court and the objectors in
2 *Perrigo* by making the labeling changes permanent.⁷

3 Of course, the Schiff Defendants are under no obligation to agree to
4 injunctive relief similar in scope to the amended relief in *Perrigo*. However,
5 absent agreed removal of key synonyms, Plaintiffs believe there is a very real risk
6 that the settlement may not be finally approved and/or withstand appeal, and have
7 thus moved to withdraw from the current settlement.⁸ And, based on their efforts
8 to learn the identities of, and thereafter communicate with potential objectors and
9 “apprise the Court if after communicating with those persons and entities, it would
10 appear that some or another modification to the Settlement might be prudent to
11 address potential objectors” (Doc. 123 at p. 11, n.8), Defendants apparently agree
12 the risk is real and modifications may be necessary.

13 **B. Defendants’ Adequacy Arguments Are Baseless.**

14 Defendants question Plaintiffs’ counsel’s adequacy to represent the class in
15 light of their motion to withdraw from the current settlement and note that even if
16 *Pearson* does require some changes to the settlement, “the only potential
17 modification is fairly obvious” and should be to lower the fees paid to Plaintiffs’
18 counsel. (Doc. 123 at pp. 19-22.⁹) Again, this contention is internally inconsistent.

19 _____
20 ⁷ The revised agreement provides that the changes will remain in place until such
21 time as the Settling Defendant (1) becomes aware of additional evidence
22 substantiating the prohibited representations and (2) obtains Court approval to
23 include them. (*Perrigo*, Doc. 141 Ex. 1 at ¶ 13.)

24 ⁸ While Plaintiffs’ counsel is not at liberty to disclose the substance of on-going
25 settlement discussions, it is likely that at least one and perhaps two other
26 glucosamine manufacturers are going to agree to injunctive relief provisions
27 similar or identical to those agreed to by *Perrigo*.

28 ⁹ This argument constitutes a breach of the Settlement Agreement. The Agreement
provides that, “Schiff will not oppose application(s) for an Attorneys’ Fee Award
of up to an aggregate amount of \$3,000,000...” (Doc. 107-1, Settlement
Agreement, VI.A.). Suggesting, as Defendants now do, that the solution to any
problems here is for the Court to not award Plaintiffs’ counsel the full amount that
Defendants agreed to pay is making a statement in opposition to such an award.

1 If a reduction in fees is the only modification required to eliminate objections and
2 ensure final approval of the settlement, there would have been no reason to delay
3 notice. Fees are determined in conjunction with final approval which occurs *after*
4 notice has issued.

5 The fact is Defendants acknowledge it would be wasteful to provide notice
6 more than once in this case. (Doc. 123 at p. 9, n.7.) Their actions also indicate
7 that modifications should be made to the settlement. Accordingly, the most
8 expeditious and efficient means of proceeding is to discuss these modifications
9 now, agree on whether and how to address them, and then seek approval of an
10 improved settlement.

11 If, however, the Court does not agree and denies the Motion to Withdraw,
12 Plaintiffs and their counsel are fully aware that they are contractually bound to
13 proceed forward with this settlement. Similarly, Defendants are contractually
14 bound to promptly implement the court ordered notice program.

15 **III. CONCLUSION**

16 As the foregoing discussion and even Defendants’ Opposition make clear,
17 both Plaintiffs and Defendants acknowledge that changes need to be made to the
18 settlement. Because they remain concerned about objections to the settlement,
19 Plaintiffs request the Court grant Plaintiffs’ *ex parte* motion to withdraw from the
20 settlement. Alternatively, if the Court denies the Motion to Withdraw, Plaintiffs’
21 request that the Court order Defendants to immediately implement the notice
22 program so the settlement process may proceed.

23 Dated: March 2, 2015

**BONNETT, FAIRBOURN, FRIEDMAN &
BALINT, P.C.**

25 By: /s/ Patricia N. Syverson
26 Patricia N. Syverson, Attorney for
27 Plaintiffs LUIS LERMA and NICK
PEARSON

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

BONNETT, FAIRBOURN,
FRIEDMAN & BALINT, P.C.
Patricia N. Syverson (Bar No. 203111)
Elaine A. Ryan (*Admitted Pro Hac
Vice*)
Lindsey Gomez-Gray (*Admitted Pro
Hac Vice*)
2325 East Camelback Road, Suite 300
Phoenix, Arizona 85016
Telephone: (602) 274-1100
Facsimile: (602) 274-1199

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.
Manfred P. Muecke (Bar No. 222893)
600 W. Broadway, Suite 900
San Diego, California 92130
Telephone: (619) 756-7748
Facsimile: (602) 274-1199

BOODELL & DOMANSKIS LLC
Stewart M. Weltman (*Admitted Pro Hac
Vice*)
sweltman@boodlaw.com
353 N. Clark St. Suite 1800
Chicago, IL 60604
Telephone: (312) 938-1670

Attorneys for Plaintiffs
LUIS LERMA and NICK PEARSON

Dated: March 2, 2015

DENLEA & CARTON LLP

By: /s/ Jeffery I. Carton
Jeffrey I. Carton, Attorney for Plaintiff
MURIEL JAYSON
DENLEA & CARTON LLP
Jeffrey I. Carton
Robert J. Berg
One North Broadway, Suite 509
White Plains, New York 10601
Telephone: (914) 920-7400
Facsimile: (914) 761-1900

CRIDEN & LOVE PA
Kevin Bruce Love
7301 SW 57th Court, Suite 515
South Miami, Florida 33134
Telephone: (305) 357-9000
Facsimile: (305) 357-9050

Attorneys for Plaintiff MURIEL
JAYSON

{00391666 }

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

CERTIFICATE OF SERVICE

I hereby certify that on March 2, 2015, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF system which will send notification of such filing to the e-mail addresses denoted on the Electronic mail notice list.

I certify under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed on March 2, 2015.

/s/ Patricia N. Syverson
Patricia N. Syverson

EXHIBIT A

-----Original Message-----

From: MARK.MESTER@lw.com [mailto:MARK.MESTER@lw.com]
Sent: Wednesday, February 25, 2015 11:14 AM
To: Stewart Weltman
Subject: RE: Lerma v. Schiff

I have. If any other objectors contacted you about Lerma, however, we would obviously like to know.

From: Stewart Weltman
Sent: Wednesday, February 25, 2015 8:16:24 AM
To: Mester, Mark (CH); Ms. Elaine Ryan; Lally, Kathleen (CH); Patricia N. Syverson
Subject: Fwd: Lerma v. Schiff

Mark - I just received this email. Have you spoken to her yet.

Sent from my iPhone

Begin forwarded message:

From: Laura Smith <lsmith@truthinadvertising.org<mailto:lsmith@truthinadvertising.org>>
Date: February 25, 2015 at 10:10:02 AM CST
To: Stewart Weltman <sweltman@weltmanlawfirm.com<mailto:sweltman@weltmanlawfirm.com>>
Subject: Lerma v. Schiff

Stewart,

This is to confirm that Truth in Advertising (TINA.org<<http://TINA.org>>) plans on filing an amicus brief opposing the terms of the current settlement agreement pending in the Lerma v. Schiff case. The timing of our filing depends on whether two other organizations that have expressed interest in this case decide to join our brief.

If you have any questions, please don't hesitate to contact me.

Sincerely,

Laura

Laura Smith
Legal Director
203-421-6210 | lsmith@truthinadvertising.org<mailto:lsmith@truthinadvertising.org>
truthinadvertising.org<http://truthinadvertising.org/> | @TruthinAd |
facebook.com/truthinad<http://facebook.com/truthinad>

[https://www.truthinadvertising.org/wp-content/uploads/2014/12/New-Email-Signature-Image-2.png]

This email may contain material that is confidential, privileged and/or attorney work product for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies.

Latham & Watkins LLP

EXHIBIT B

From: Laura Smith
<lsmith@truthinadvertising.org>
Date: January 21, 2015 at 2:48:43 PM EST
To: sweltman@weltmanlawfirm.com
Subject: Status of Lerma v. Schiff Nutrition

Mr. Weltman,

My name is Laura Smith and I'm the Legal Director at Truth in Advertising. I'm reaching out to you to learn the status of the Lerma v. Schiff Nutrition litigation in which you're involved. As I mentioned in my voicemail, we were getting ready to object to the terms of the proposed settlement agreement reached in that case but noticed that the parties moved for a stay as a result of the Pearson decision. Would you mind telling me the status of the case at this point in time? Will there be a new proposed settlement agreement or do you intend to proceed at the final fairness hearing on April 8?

Many thanks in advance.

Sincerely,

Laura

Laura Smith

Legal Director

203-421-6210 | lsmith@truthinadvertising.org

truthinadvertising.org | @TruthinAd
| facebook.com/truthinad

